Beilu Pharma(300016)2024-07-09 08:07Strategic Development - The company aims to become one of the "Top 100 Pharmaceutical Manufacturing Enterprises in China" with a dual-driven business model of "chemical drugs + traditional Chinese medicine" [3] - The company has completed the acquisition of 80% equity of Tianyuan Pharmaceutical, making it an important subsidiary of Beilu Pharmaceutical [3] - The company is focusing on expanding its traditional Chinese medicine (TCM) sector, with the construction of the Bozhou production base as a key strategic layout [3] R&D and Innovation - In 2023, the company's R&D investment reached 122.3289 million yuan, a year-on-year increase of 22.62% [3] - The company is actively developing new products in areas such as contrast agents, central nervous system, endocrine, digestive system, and external preparations [3] - The company is strengthening R&D cost management and improving R&D efficiency to lay a solid foundation for long-term development [3] Production and Operations - The Bozhou production base, which started construction in March 2024, will enhance production capacity for granules, tablets, capsules, and pills [3] - The company is integrating Tianyuan Pharmaceutical into its operational system through collaboration in production, marketing, procurement, and finance [2] - The company is leveraging its marketing system, including in-hospital self-operation, agency, retail, and e-commerce channels, to expand market share [2] Market Expansion and Product Potential - The company sees significant market potential for Tianyuan Pharmaceutical's core product, Jinlianhua Granules, and aims to increase its market share [2] - The company is committed to building the "First Brand of Anti-Anxiety" with its exclusive TCM product, Jiuwei Zhenxin Granules [3] - The company expects the integration and synergy with Tianyuan Pharmaceutical to drive future market growth and profitability [2]